Protective effects of monoclonal antibody to intercellular adhesion molecule-1 in venous ischemia-reperfusion injury: experimental study in rats.
Flaps with venous occlusion have a decreased survival rate compared with arterial occlusion. It seems that several factors are involved in the etiology of total venous occlusion, including free radicals, edema, thrombosis, and reperfusion injury. In the present study, the authors evaluated the blockage of polymorphonuclear leukocyte endothelial adhesion by using a monoclonal antibody to the intercellular adhesion molecule 1 (ICAM-1) ligand to prevent venous ischemia-reperfusion injury in rat epigastric island flaps. A skin flap (3 x 4 cm) supplied by the superficial epigastric artery and vein was harvested unilaterally in 40 male Wistar rats. Total venous occlusion of the skin flap was achieved. Arterial inflow was left intact. Rats were randomly divided into four groups (n = 10). In Group 1; rats were intravenously pretreated with 0.5 ml of 0.9 percent normal saline 15 min before applying a venous clamp, and the flaps were subjected to 6 hr of venous ischemia. In Group 2; rats were intravenously pretreated with 0.05 mg of monoclonal antibody to the intercellular adhesion molecule 1 (0.20 mg/kg) in 0.5 ml of 0.9 percent normal saline 15 min before applying the venous clamp, and the flaps were subjected to venous ischemia as in Group 1. In Group 3; rats were pretreated as in Group 1, and the flaps were subjected to 8 hr of venous ischemia. In Group 4; rats were pretreated as in Group 2, and the flaps were subjected to 8 hr of venous ischemia. The flaps were assessed histologically and by measuring viable and non-viable areas on postoperative day 7. Flap measurements revealed that blocking the action of ICAM-1 IN VIVO by administering monoclonal antibody significantly attenuated ischemic injury after 6 or 8 hr of venous occlusion.
Demirseren
Mustafa Erol
ME
Department of Plastic, Reconstructive and Aesthetic Surgery, Ataturk Training and Research Hospital, Ankara, Turkey.
Sarici
Murat
M
Gokrem
Serdar
S
Yenidunya
Sibel
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002448:Cell Adhesion / Q000187:drug effects; D004730:Endothelium, Vascular / Q000187:drug effects; D019074:Epigastric Arteries / Q000187:drug effects; D006083:Graft Occlusion, Vascular / Q000209:etiology; D006085:Graft Survival; D018799:Intercellular Adhesion Molecule-1 / Q000187:drug effects*; D007511:Ischemia / Q000209:etiology; D008297:Male; D009504:Neutrophils / Q000187:drug effects; D020011:Protective Agents / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000517:prevention & control*; D016038:Skin Transplantation / Q000473:pathology; D013524:Surgical Flaps / Q000098:blood supply; D014022:Tissue Survival
D000911:Antibodies, Monoclonal; D020011:Protective Agents; D018799:Intercellular Adhesion Molecule-1